U.S. Banks Stock News

NYSE:ECVT
NYSE:ECVTChemicals

Assessing Ecovyst (ECVT) Valuation After Stronger Quarterly Earnings And Buyback Completion

Stronger quarter and completed buyback put Ecovyst stock in focus Ecovyst (ECVT) has drawn fresh attention after first quarter 2026 results showed sales of US$214.95 million and a return to profitability, alongside completion of a multi year US$303.47 million share repurchase program. See our latest analysis for Ecovyst. The stronger first quarter and sizeable completed buyback appear to sit behind Ecovyst’s recent momentum, with a 90 day share price return of 26.25% and a 1 year total...
NasdaqGS:COLL
NasdaqGS:COLLPharmaceuticals

A Look At Collegium Pharmaceutical (COLL) Valuation As Earnings Jump And AZSTARYS Acquisition Is Proposed

Collegium Pharmaceutical (COLL) is back in focus after reporting first quarter 2026 earnings that showed a sharp jump in profitability and progress across its ADHD and pain portfolios, alongside a proposed AZSTARYS acquisition. See our latest analysis for Collegium Pharmaceutical. Despite the strong first quarter earnings and the proposed AZSTARYS deal, Collegium Pharmaceutical’s share price performance has been mixed. The 7 day share price return was 9.31%, but the 90 day share price return...
NYSE:BLD
NYSE:BLDConsumer Durables

Did TopBuild’s (BLD) Profit Squeeze Amid Rising Sales Just Shift Its Investment Narrative?

TopBuild Corp. has already reported first-quarter 2026 results, with sales rising to US$1,445.86 million from US$1,233.28 million a year earlier, while net income decreased to US$104.81 million from US$123.39 million. The combination of higher revenue but lower net income and earnings per share highlights pressure on TopBuild’s profitability despite ongoing top-line growth. Next, we’ll examine how this mix of revenue growth and thinner earnings margins may influence TopBuild’s investment...